3.4 News
  • Press Releases
  • In the News
  • Additional Partnership
  • Blog

September 9, 2021

‘Molecular Twin’ Initiative Will Help Advance Precision Cancer Treatment

Cedars-Sinai Cancer and Tempus, a leader in artificial intelligence and precision medicine, are harnessing the power of big data and AI to design personalized cancer treatment options by creating virtual replicas of patients’ DNA, RNA, protein and other information to help identify the most effective approach to each...

August 17, 2021

Tempus Submits PMA Application to the FDA for its xT-Onco Assay

Tempus, a leader in artificial intelligence and precision medicine, today announced the submission of a Premarket Approval (PMA) application for its proprietary broad-panel DNA sequencing assay to the U.S. Food and Drug Administration (FDA).  Tempus is seeking approval for its xT-Onco assay, a broad-panel next-generation sequencing-based, in vitro diagn...

August 4, 2021

Tempus Announces New Genomic Sequencing Lab in Research Triangle Park in Durham, NC

Tempus, a leader in artificial intelligence and precision medicine, today announced its new, state-of-the-art genomic sequencing lab in Durham’s Research Triangle Park (RTP). The 52,000-square foot space marks Tempus’ third laboratory, joining the company’s existing CAP-accredited/CLIA-certified labs in Atlanta and its Chicago headquarters.  RTP’s proximit...

July 28, 2021

Tempus Unveils Its Scalable Tumor Organoid Screening Platform In Cell Reports Study

Tempus, a leader in artificial intelligence and precision medicine, today announced publication of a study outlining the precision medicine applications for its patient-derived tumor organoid (TO) platform. The study demonstrates how the platform has the potential to accelerate the application of patient derived biological models (organoids) in precision oncology...

Tempus Unveils Its Scalable Tumor Organoid Screening Platform  In Cell Reports Study

July 12, 2021

Tempus xF Liquid Biopsy Assay Demonstrates Extensive Analytical and Clinical Validity in npj Precision Oncology Study

Tempus, a leader in artificial intelligence and precision medicine, today announced results from validation studies demonstrating the reliable analytical performance of the Tempus|xF liquid biopsy. When validated against methods such as ddPCR, the Roche AVENIO kit, and the Tempus|xT solid tumor assay, xF demonstrated high sensitivity an...

July 8, 2021

Tempus Announces Leadership Team Expansion Including Chief Commercial Officer and Chief Financial Officer

Tempus, a leader in artificial intelligence and precision medicine, today announced the addition of six new hires to the leadership team, including a new Chief Commercial Officer, Chief Financial Officer, General Counsel, and the company’s first Chief Accounting Officer, Senior Vice President of Marketing, and Senior Vice President of Cor...

June 1, 2021

Tempus Announces Eleven Abstracts Accepted for Presentation at the 2021 American Society of Clinical Oncology Annual Meeting

Tempus, a leader in artificial intelligence and precision medicine, today announced eleven abstracts accepted for presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting taking place virtually from June 4 – 8. “These high impact ASCO presentations from Tempus collaborators and investigators illustrate the power of over 35...

May 20, 2021

Tempus Unveils Its Lens Platform, Offering Unparalleled Access to One of the World’s Largest De-Identified Clinical and Molecular Datasets

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its cloud-based data and analytics platform, Lens. The all-in-one platform will provide scientists and researchers across biotechnology and pharmaceutical companies with short term, on demand access to more than 35 petabytes of de-identified cli...

May 19, 2021

Leading Real-World Data and Analytics Organizations Form Industry Coalition to Advance Policies to Support Regulatory Use of Real-World Evidence

Five real-world data (RWD) and analytics organizations today announced an industry coalition dedicated to advancing the use of real-world evidence (RWE) to support regulatory decisions. Founding members of the RWE Alliance are Aetion, Flatiron Health, IQVIA, Syapse, and Tempus. The RWE Alliance intends to...

April 7, 2021

Tempus Announces Abstracts to be Presented at the American Association for Cancer Research Annual Meeting 2021

Tempus, a leader in artificial intelligence and precision medicine, today announced abstracts accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will convene virtually on April 10-15 and May 17-21. The research leverages Tempus’ unparalleled library of multi-modal data to facilitate discovery, development, and delivery of opt...

Show More